Di Giacomo cites CAR‑T survival boost

CAR-T cells are engineered immune cells — basically a patient’s own T cells rewired to recognize a target on cancer. They have been spectacular in some blood cancers, but solid tumors have been the graveyard for the field. The problem is not just finding the tumor. It is getting the cells to survive, keep working, and avoid burning out inside a hostile tumor environment. (thelancet.com) What changed here is that a Claudin18.2-targeted CAR-T therapy, satricabtagene autoleucel or satri-cel, became the first randomized phase 2 CAR-T win in a solid tumor, in patients with advanced gastric or gastro-oesophageal junction cancer. ### What actually happened? In the CT041-ST-01 trial, patients in China with HER2-negative, CLDN18.2-positive advanced gastric or GEJ cancer who had already failed at least two prior lines of therapy were randomized to satri-cel or physician’s-choice treatment. (fda.gov) The study was open-label, phase 2, and multicenter — important because this was not just a single-arm “looks promising” signal. ### Why is CLDN18.2 the target? CLDN18.2 is a tight-junction protein isoform that shows up in a meaningful slice of gastric cancers and is relatively restricted in normal tissues, which makes it one of the cleaner solid-tumor targets people have found. That does not make the biology easy, but it gives CAR-T cells something real to lock onto instead of chasing a fuzzy marker. (thelancet.com) ### What were the numbers? The headline survival figure was 7.9 months median overall survival for satri-cel versus 5.5 months for control. Median progression-free survival was 3.3 months versus 1.8 months. That is not a cure. But in heavily pretreated metastatic gastric cancer, a gain like that is why people paid attention. The catch is that some analysts noted the control arm underperformed expectations, so the result is strong but still needs replication. (thelancet.com) ### Why is this a big deal for CAR-T? Because solid tumors usually beat CAR-T with attrition. The cells do not expand enough, they do not persist long enough, and they get exhausted. That is why people keep reaching for CRISPR screens and other engineering tricks — not as science-project extras, but as ways to identify knockouts that help CAR-T cells proliferate, resist exhaustion, and keep killing. (thelancet.com) A 2025 Nature paper built exactly that kind of discovery platform and highlighted edits such as RHOG knockout, alone or with FAS knockout, as ways to boost function in preclinical models. ### So did CRISPR cause this survival gain? No — at least not in the clinical result people are talking about here. The survival boost came from satri-cel, an autologous CLDN18.2 CAR-T product tested in a randomized trial. The CRISPR-screen story is adjacent context. (thelancet.com) It matters because it points to the next design wave: not just choosing a target, but systematically editing the cells to persist longer and fail less often. ### What about safety? This is where the mood gets more cautious. In April 2024, FDA required boxed warnings for approved BCMA- and CD19-directed autologous CAR-T products after reports of T-cell malignancies, including CAR-positive tumors, and said patients should be monitored for life for secondary malignancies. NCI later highlighted that the evidence is mixed — one large series found no sign the CAR caused the lymphoma, while one case study suggested the treatment probably contributed. (nature.com) ### Why does that matter for future designs? Because every extra engineering step can improve function but also complicate the safety and manufacturing story. If the field moves toward CRISPR-enriched or multi-edited CAR-T cells for solid tumors, regulators will want cleaner proof that the edits help without creating new long-tail risks. (thelancet.com) That does not kill the approach. It just raises the bar. ### Bottom line? The real news is not that CAR-T suddenly solved solid tumors. It did not. The news is narrower and more important — one gastric-cancer program finally produced randomized evidence that CAR-T can beat standard treatment in a solid tumor, and the next battle is making those cells tougher without making them riskier. (fda.gov) (thelancet.com)